Could a 6-Day steroid taper cut pain and opioid use after knee surgery?
NCT ID NCT05859269
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a 6-day course of oral methylprednisolone (a steroid) after total knee replacement can reduce pain, nausea, and the need for opioid painkillers. 101 adults with knee arthritis were randomly assigned to receive either the steroid taper or standard care. The goal is to improve early recovery after a common but painful surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Methylprednisolone (Medrol Dose Pak)
- What this could lead to
- If it works, this could provide a simple, short-term way to reduce pain and nausea after knee replacement, helping patients recover more comfortably.
- What could go wrong
- This is a small, completed Phase 4 trial with 101 participants. The steroid taper may not significantly improve outcomes over standard care, and steroids carry risks like infection or blood sugar changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
101 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 95 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee. * Patients of the ages of 18 and 95 years. Exclusion Criteria: * Patients with concurrent and significant injuries to other bones or organs. * Minors unable to consent for participation in the study. * Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * Patients with pre-existing immune suppression, where further immune suppression with glucocorticoids could warrant unwarranted or unneeded risk.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Knee arthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory Musculoskeletal Institute
Atlanta, Georgia, 30329, United States
-
Emory University Orthopaedics & Spine Hospital
Tucker, Georgia, 30084, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot to the knee: gene therapy tested against arthritis pain
- Can a diabetes drug improve joint replacement outcomes?
- Light exercise with a blood pressure cuff may rebuild leg muscle after knee replacement
- CBD tablets tested for knee pain relief in new study
- Surgeons can do nerve blocks just as well as anesthesiologists for knee replacement pain
- New drug aims to cut opioid use after knee replacement